This article is intended for primary care clinicians, oncologists, obstetrician-gynecologists, surgeons, and other specialists who care for women with breast cancer.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 300 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/07. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity. AAFP credit is subject to change based on topic selection throughout the accreditation year.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME Released: 8/19/2008
Valid for credit through: 8/19/2009, 11:59 PM EST
processing....
August 19, 2008 — Researchers have identified several risk factors that increase the risk for joint symptoms in postmenopausal women with breast cancer who are receiving endocrine treatment. The finding is reported in the August 13 Online First issue of The Lancet Oncology.
The risk for joint symptoms is increased by 12.1% by previous use of hormone replacement therapy, 7.3% by hormone receptor positivity, 6.5% by previous chemotherapy, 6.2% by obesity, and 4.9% by treatment with anastrozole vs tamoxifen.
The presence of multiple risk factors also increased the risk for joint symptoms that include arthralgia and arthritis. "The effects of these risk factors are additive, so having multiple factors will have a big impact on the likelihood of experiencing symptoms," study author Jack Cuzick, PhD, from Cancer Research UK, Wolfson Institute of Preventive Medicine, London, United Kingdom, told Medscape Oncology.
Estrogen deficiency and postmenopausal status have been associated with the development of joint pain and other symptoms in the general population. In addition, patients with breast cancer who received chemotherapy have also shown joint symptoms and other joint or muscle-related problems, but tamoxifen use appears to have limited effect on the incidence of joint symptoms.
In this trial, Dr. Cuzick and colleagues investigated the relative importance of several risk factors for joint symptoms in women who were enrolled in the Arimidex Tamoxifen Alone or in Combination (ATAC) trial and then evaluated if the identified risk factors act differently in the presence of anastrozole treatment.
The ATAC trial randomly selected 9366 postmenopausal women with early breast cancer to either anastrozole 1 mg/day, tamoxifen 20 mg/day, or to a combination of both agents. Of this cohort, 5433 women (anastrozole group: n = 2698; tamoxifen group: n = 2735) who did not report joint symptoms at entry into the trial were included in the analysis, which was based on data from case reports for these patients.
For the study authors' analysis, joint symptoms were defined as any report of arthralgia, arthrosis, arthritis, or joint disorder on a case-report form, and joint disorders included reports of cervical spondylosis, osteoarthritis, and disk herniation.
The investigators found that women in the anastrozole group reported significantly more joint symptoms vs women in the tamoxifen group (949 [35.2%] of 2698 vs 829 [30.3%] of 2735 women, respectively). In both groups, the majority of joint symptoms were mild or moderate, and the intensity of symptoms was similar across both groups. Of patients who reported joint symptoms, 60% received treatment, and 90% used a nonsteroidal anti-inflammatory drug alone or in combination with a mild analgesic.
Of the 1914 women who used hormone replacement therapy before entry into the trial, 777 (40.6%) went on to have joint symptoms vs 1001 (28.4%) of 3519 women who had not used hormonal therapy. Patients with hormone receptor–negative breast cancer had significantly fewer joint symptoms vs patients with hormone receptor–positive tumors (124 [26.9%] of 461 vs 1556 [34.2%] of 4548 patients, respectively).
Previous chemotherapy and high body mass index (BMI) were also associated with an increase in risk factors. Women who initially underwent chemotherapy had significantly more joint symptoms than those who did not undergo chemotherapy (461 [37.8%] of 1219 vs 1317 [31.3%] of 4214 women, respectively). Patients with a BMI of more than 30 kg/m² reported more joint symptoms vs patients who had a BMI of 25 to 30 kg/m² (504 [37.2%] of 1354 vs 502 [31.3%] of 1926 women) or a BMI of less than 25 kg/m² (592 [31.0%] of 1908 women).
The researchers noted that the effect of previous hormone replacement therapy was especially striking because most women had stopped using it within 6 months before they entered the study. However, the effect was similar in patients who had halted hormonal therapy earlier. The effects of hormone replacement therapy also appeared to be additive, resulting in an 18.1% increase in joint symptoms in women with both previous use of hormone replacement therapy and who were receiving anastrozole vs women receiving tamoxifen with no previous hormone replacement therapy.
Women who recently used hormone replacement therapy were more likely to have experienced a greater decrease in estrogen concentrations with endocrine treatment than women who stopped use more than 6 months ago, the study authors write, and most studies have shown that these women are more likely than never-users to have estrogen receptor–positive tumors.
In most patients, the risk for joint symptoms does not override the clear benefits of anastrozole vs tamoxifen in decreased tumor recurrence rates and fewer other major adverse effects. "This is a clinical judgment but even one factor should be enough to prompt oncologists to counsel patients about the possibility of joint symptoms and the likelihood that they will be mild and transient," said Dr. Cuzick.
"If symptoms are severe or persistent, tamoxifen should be considered instead of an aromatase inhibitor," he added.
This study was funded by Cancer Research UK and AstraZeneca. Dr. Cuzick has received research funds from AstraZeneca and acted as a consultant to AstraZeneca and Novartis. Four of the other study authors have disclosed various financial relationships with AstraZeneca. Another study author has received honoraria and other research grants from AstraZeneca, Pfizer, Genentech, Lilly, Taiko, and Amgen.
Lancet Oncol. Published online August 13, 2008.
Estrogen concentrations appear to be inversely related to joint symptoms in women, and multiple lines of evidence point to this conclusion. Joint symptoms are most prominent in women in the fifth decade of life, and women who are postmenopausal are more likely to experience joint symptoms vs premenopausal or perimenopausal women of the same age. Hormonal therapy with estrogen can relieve these joint symptoms. Conversely, third-generation aromatase inhibitors, which reduce estrogen levels by decreasing the conversion of androgens to estrogen, promote joint symptoms.
The current study analyzes the ATAC trial to determine factors that promote joint symptoms in women receiving adjuvant therapy for breast cancer.